Assertion: intravenous immunoglobulin | /r/HasProperty | ivig
Facets:
Source sentences:
text: However, presently, intravenous immunoglobulin (IVIG) replacement therapy is generally accepted as the treatment of choice for selected patients with IgG subclass deficiency and persons with other immunodeficiencies including primary immune deficiencies.  
text: Patients with immunodeficiencies or some types of autoimmune diseases rely on a safe therapy with intravenous immunoglobulins (IVIGs) manufactured from human plasma, the only available source for this therapeutic.
text: Serum ST6GAL1 is also implicated in the sialylation of IgG, enabling binding to inhibitory FcγRIIb, the primary mechanism by which intravenous immunoglobulin (IVIG) alleviates autoimmune disease (18–20).
text: Acute hemolysis in a patient with cytomegalovirus pneumonitis treated with intravenous immunoglobulin (IVIG).
text: Aetna considers the use of intravenous immunoglobulin (IVIG) therapy or subcutaneous immunoglobulin (SCIG) therapy medically necessary in members with the conditions specified below: Primary Immunodeficiency - considered medically necessary for members with any of the following diagnoses: Severe combined immunodeficiency (SCID) or congenital agammaglobulinemia (eg, X-linked or autosomal recessive agammaglobulinemia)
text: The possible role of intravenous immunoglobulin (IVIG) in patients with DAH due to vasculitis or other connective tissue disease is unknown”.
text: Lack of implications of C-type lectin receptors and activating FcγRIIA in mediating β-catenin activation by intravenous immunoglobulin (IVIG) in dendritic cells.
text: 5: Intact IgG is mandatory for the β-catenin activation by intravenous immunoglobulin (IVIG).
text: However, presently, intravenous immunoglobulin (IVIG) replacement therapy is generally accepted as the treatment of choice for selected patients with IgG subclass deficiency and persons with other immunodeficiencies including primary immune deficiencies.  
text: Intravenous immunoglobulin (IVIG)
text: Coagulation factors (II, VII, IX, X, and particularly XIa) remaining in high concentrations in intravenous immunoglobulin (IVIG) preparations can form thrombi, causing thromboembolic events, and in serious cases, result in death.
text: This Example illustrates the pasteurization of intravenous immunoglobulin (IVIG).
text: In this study, twenty-nine samples of intravenous immunoglobulin (IVIG) from eight different manufacturers were assayed for procoagulant activity.
text: This Example illustrates the pasteurization of intravenous immunoglobulin (IVIG).
text: The immunomodulatory potential and low incidence of severe side effects of high-dose intravenous immunoglobulin (IVIg) treatment led to its successful application in a variety of dermatological autoimmune diseases over the last two decades.
text: The immunomodulatory potential and low incidence of severe side effects of high-dose intravenous immunoglobulin (IVIg) treatment led to its successful application in a variety of dermatological autoimmune diseases over the last two decades.
text: The use of intravenous immunoglobulin (IVIg) as an alternative to antibiotic prophylaxis remains contraversial also in symptomatic THI patients.
text: Sporadic reports suggest that intravenous immunoglobulin (IVIg) may be efficacious in the influenza setting.
text: Intravenous immunoglobulin (IVIG) contains the pooled immunoglobulin G (IgG) immunoglobulins from the plasma of approximately a thousand or more blood donors.
text: For such patients, intravenous immunoglobulin (IVIG) replacement may be an option.
text: Intravenous immunoglobulin (IVIG) is a treatment thought to reset the immune system.
text: Preferably, standard conditions are used to precipitate Fraction II from the solution, which is then further purified to provide a pharmaceutical product such as intravenous immunoglobulin (IVIG) or subcutaneous immunoglogulin (SCIG).
text: Intravenous immunoglobulin (IVIG) has been shown to be ineffective for the prophylaxis of, and as a treatment adjunct in, infections in some high-risk, preterm, low-birth-weight neonates (USPDI, 2002).
text: Intravenous immunoglobulin (IVIG) stimulates β-catenin signaling in dendritic cells.
text: Intravenous immunoglobulin (IVIG) activates β-catenin in human dendritic cells in an IgG-sialylation independent manner.
text: In patients with myasthenia gravis who are being initiated on eculizumab therapy because their disease is refractory to standard treatments, the safety of an abbreviated washout period in transitioning from intravenous immunoglobulin (IVIG) to eculizumab has not been determined.
text: The present invention, therefore, is applicable to pasteurization of a wide variety of native and modified immunoglobulin solutions, including solutions of gammaglobulin (IgG), the mixture of immunoglobulins obtained directly from blood and comprising mainly gammaglobulin and less than 5% of other classes of immunoglobulins including IgA, IgM and IgE, intravenous immunoglobulin (IVIG), hyperimmune globulins, such as Rho(D) immune globulin and hepatitis B immune globulin, a monoclonal antibody of the IgG class, preferably of the IgG1 subclass, and a human myeloma protein of the IgG class, preferably of the IgG1 subclass.
text: Patients with multiple myeloma also receive supportive treatments, such as transfusions to treat low blood cell counts, and antibiotics and sometimes intravenous immunoglobulin (IVIG) for infections.
text: Intravenous immunoglobulin (IVIG) preparations are increasingly used for the treatment of a variety of immunological deficiencies and autoimmune disorders including dermatomyositis, idiopathic thrombocytopenic purpura, Kawasaki disease, and Guillain-Barré syndrome.
text: Intravenous immunoglobulin (IVIG).
text: The present invention, therefore, is applicable to pasteurization of a wide variety of native and modified immunoglobulin solutions, including solutions of gammaglobulin (IgG), the mixture of immunoglobulins obtained directly from blood and comprising mainly gammaglobulin and less than 5% of other classes of immunoglobulins including IgA, IgM and IgE, intravenous immunoglobulin (IVIG), hyperimmune globulins, such as Rho(D) immune globulin and hepatitis B immune globulin, a monoclonal antibody of the IgG class, preferably of the IgG1 subclass, and a human myeloma protein of the IgG class, preferably of the IgG1 subclass.
text: Intravenous immunoglobulin (IVIg) is a well known medical product, which consists of a non-specific immunoglobulin solution obtained by combining plasma from a plurality of individuals.
text: states that “Routine administration of immunomodulatory therapy (e.g., glucocorticoids, plasma exchange, intravenous immunoglobulin [IVIG]) is not indicated for children who meet PANDAS criteria”.